SCHEMBL6072030

SCHEMBL6072030

N#Cc1c(-c2ccccc2Oc2ccccc2)nc2ccccc2c1N

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 4/20 0.46
ADORA1 P30542 3/20 0.46
PIP4K2A P48426 1/20 0.46
KDM4E B2RXH2 4/20 0.43
ALDH1A1 P00352 3/20 0.43
ACHE P22303 5/20 0.43
GLA P06280 3/20 0.41
HPGD P15428 2/20 0.41
CASP1 P29466 2/20 0.41
CASP7 P55210 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
HSD17B10 Q99714 2/20 0.41
POLB P06746 2/20 0.41
MAPT P10636 2/20 0.41
HTT P42858 2/20 0.41
KMT2A Q03164 2/20 0.41
RAB9A P51151 2/20 0.41
LMNA P02545 1/20 0.41
TP53 P04637 1/20 0.41
GAA P10253 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6072034 0.80 KDM4E (0.49) ADORA2AADORA1KDM4EALDH1A1GLA
SCHEMBL6072767 0.79 ADORA2A (0.60) ADORA2AADORA1PIP4K2AKDM4EALDH1A1
SCHEMBL6072331 0.79 BCHE (0.53) ADORA2AADORA1KDM4EALDH1A1ACHE
SCHEMBL9791332 0.76 ADORA1 (0.62) ADORA2AADORA1KDM4EALDH1A1ACHE
SCHEMBL17492257 0.76 ADORA2A (0.44) ADORA2AADORA1ALDH1A1HPGDSMN1; SMN2
SCHEMBL7913436 0.76 ABCC8 (0.58) ADORA2AADORA1KDM4EALDH1A1HPGD
SCHEMBL6072047 0.75 ACP1 (0.45) ADORA2AADORA1PIP4K2AKDM4EALDH1A1
SCHEMBL6072087 0.73 ADORA1 (0.65) ADORA2AADORA1PIP4K2AKDM4EALDH1A1
SCHEMBL12681344 0.71 ALDH1A1 (0.45) ADORA2AKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL6252164 0.71 KDM4E (0.60) ADORA2AADORA1KDM4EALDH1A1ACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060264460-A1 3-Cyanoquinoline inhibitors of Tpl2 kinase and methods of making and using the same WYETH (US) 2006-11-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060264460-A1 3-Cyanoquinoline inhibitors of Tpl2 kinase and methods of making and using the same TNNI3K, CSNK1A1L, CDKL1 ADORA2A 2729/4885ADORA1 2355/4885PIP4K2A 340/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.